- In May 2024, Edwards Lifesciences announced the introduction of its SAPIEN 3 Ultra RESILIA valve in Europe. This innovative transcatheter aortic heart valve features the company's advanced RESILIA tissue technology, which enhances durability for long-term use. Additionally, the device has received CE marking for the treatment of patients with heart valve disease resulting from native calcific aortic stenosis, marking a significant advancement in therapeutic options
- In April 2024, Medtronic unveiled its next-generation surgical aortic tissue valve, the Avalus Ultra Bioprosthesis. This advanced device is designed to facilitate ease of implantation, enhance visibility for future valve-in-valve procedures, and provide convenient sizing options. Additionally, the valve features a polyetheretherketone (PEEK) base frame, ensuring consistent circularity for improved performance and reliability
- In January 2023, Abbott secured U.S. FDA approval for its Navitor transcatheter aortic valve implantation (TAVI) system. This innovative device is intended for patients suffering from severe aortic stenosis, particularly those who are at high surgical risk due to potential complications. The approval of Navitor marks a significant advancement in treatment options for this patient population, offering a less invasive solution for managing aortic valve disease
